Advertisement

The U.S. Food and Drug Administration has granted a second orphan drug designation to Waltham ophthalmologic device and pharmaceutical developer Avedro Inc. for a treatment of corneal ectasia. The designation relates to VibeX, its riboflavin solution intended for use with UVA irradiation, the KXL system for Corneal Cross-linking, which the company said on its website helps strengthen the cornea following refractive surgery.

SOURCE

Advertisement
Advertisement